The neuroprotective effects of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), GYKI 52466, and MK-801 were tested following severe fore brain ischemia. Wistar rats were subjected to 10 min of normothermic ischemia and reperfused for 7 days. Ne crotic hippocampal CAl neurons were counted and ex pressed as a percentage (mean ± SD). In Experiment I, saline-treated rats sustained 81 ± 20% damage to dorsal CAl' Rats given NBQX 30 mg/kg i.p. x3 lost 21 ± 27% (p < 0.01). Neither MK-80l I mg i.p. x3 alone, nor in combination with the cytoprotective dose of NBQX pro tected CAl' with 83 ± 18 and 54 ± 34% damage, respec tively (NS). Giving NBQX 90 mg/kg i.v. did not protect cells (94 ± 5%) and resulted in nephrotoxicity. In Exper iment 2, rats were given saline or three doses of NBQX 30 mg/kg i.p. immediately at reperfusion (RP) or after a 6-, 12-, or 24-h delay. Saline-treated rats suffered 79 ± 16%
Transient but severe forebrain ischemia causes irreversible neuronal degeneration to highly sensi tive regions of the brain. In particular, the CA I hip pocampus is exquisitely vulnerable to delayed dam age following ischemia (Kirino, 1982; Pulsinelli et aI., 1982) . Glutamate, released into the extracellular space during ischemia, has been thought to play a central role in the initiation of this postischemic, delayed, selective neuronal degeneration (Ben veniste et aI., 1984) , although a detailed understand ing of the mechanism of molecular cell death is still injury. NBQX given immediately resulted in 17 ± 17% injury, and even if treatment was delayed by either 6 or 12 h, there was marked protection with only 27 ± 32 and 25 ± 17% injury, respectively (all p < 0.01). Delaying the initiation of treatment to 24 h was not successful, result ing in 50 ± 28% injury (NS). In Experiment 3, saline treated rats lost 81 ± 19% of CAl cells, while those given GYKI 52466 10 mg/kg i.p. x5 starting immediately fol lowing RP lost 80 ± 14%. Blocking a-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMP A) receptors with NBQX postischemia is highly efficacious, indicating that delayed degeneration of CAl cells is AMPA rather than N-methyl-o-aspartate (NMDA) receptor-linked and is re versible for CAl cells for at least 12 h. Key Words: (X Amino-3-hydroxy-5-methyl-4-isoxazole propionate an tagonists-CAl hippocampus-Cerebral ischemia-Ex citotoxicity-N-Methyl-o-aspartate antagonists-Rats.
incomplete. Extracellular glutamate can interact with three distinct subtypes of receptors linked to ionophores: N-methyl-D-aspartate (NMDA), a-ami no-3-hydroxy-5-methyl-4-isoxazole proprionate (AMPA), and kainate receptors, as well as the me tabotropic glutamate receptor. The NMDA antago nists, both competitive (Simon et aI., 1984) and non competitive (Gill et aI., 1987) potent ion channel blockers, have been suggested to be cytoprotective in vivo for CAl cells following ischemia. This "pro tective" effect may be related to drug-induced post ischemic hypothermia rather than direct receptor antagonism (Buchan and Pulsinelli, 1990; Corbett et aI., 1990) . MK-801 and other NMDA antagonists failed to demonstrate cytoprotection following se vere forebrain ischemia when rats were kept nor mothermic during both ischemia and reperfusion (RP) (Buchan et aI., 1991b; Nellgard et aI., 1991a) .
Postischemic manipulation of non-NMDA gluta-mate receptors such as the AMP A receptor is now possible given the recent development of 2,3dihydroxy-6-nitro-7 -sulfamoy lbenzo(f)quinoxaline (NBQX) (Honore et aI. , 1988; Sheardown et aI., 1990) and GYKI 52466 [l-(4-aminophenyl)-4-meth yl-7,8-methylendioxyl-5H-2,3-benzodiazepine hy drochloride] (Tarnawa et aI., 1990 (Tarnawa et aI., , 1992 Ouardouz and Durand, 1991) , potent, but selective, AMPA antagonists. The aim of this study was to determine the postischemic effects of the sodium salt of NBQX and GYKI 52466 using the four-vessel oc clusion (4VO) model of severe forebrain ischemia (Pulsinelli and Brierley, 1979) . Following the estab lishment of a consistent cytoprotective dose of NBQX by increasing the interval from ischemia to the initial treatment with NBQX, we have been able to test the conjecture that the AMPA receptor may play a more critical role (vis-a-vis NMDA) (Buchan et aI., 1991a; Diemer et aI., 1992; LePeillet et aI. , 1992; Nellgard and Wieloch, 1992; Pulsinelli and Cho, 1992) in the delayed, but selective, loss of CAl neurons, and have determined the critical interval during which cells at risk remain viable.
MATERIALS AND METHODS

4VO preparative surgery
Male Wistar rats weighing 175-200 g were exposed to transient severe normothermic forebrain ischemia using a modified 4VO model (Pulsinelli and Brierley, 1979; Pulsinelli and Buchan, 1988) . Animals were anesthetized with 1-2% halothane, 70% N2, and 28% 02' Both com mon carotid arteries were isolated and a ligature gently placed around each vessel. The vertebral arteries were electrocauterized and a ligature was passed ventral to the cervical and paravertebral muscles but dorsal to the tra chea, esophagus, external jugular veins, and common ca rotid arteries. The free ends of this ligature were taped to the nape of the neck. The rats were allowed to recover from this preparative surgery overnight.
Ischemia
Following local anesthesia to the ventral wound, the animals were gently restrained, the surgical clip removed, and the ligatures surrounding the carotid arteries tight ened, resulting in 4VO. Loss of consciousness was seen within 10-15 s, associated with running behavior and loss of righting reflexes. The ligature surrounding the paraver tebral musculature was then tightened to prevent the opening of collateral blood flow channels and to ensure that the pupils became bilaterally fixed and dilated. A rectal temperature probe was connected to a temperature controller coupled to a heat lamp and maintained temper ature at 37.5 ± 0.5°C throughout the ischemic period. Tympanic temperature dropped to 36.5 ± OSC.
Animals were observed throughout the lO-min isch emic interval, at the end of which they were checked for unresponsiveness and dilated pupils. The carotid liga tures were removed, the vessels inspected for patency, and the wound closed with a surgical clip. Comatose an imals were returned to their cages with a rectal probe in J Cereb Blood Flow Metab. Vol. 13, No.6, 1993 situ so that normothermia could be maintained through out the recovery period. Animals that did not remain un responsive throughout the ischemic period and those that developed seizures or died were excluded from the study.
Experimental paradigms
Experiment 1 (NBQX + MK-80J). Fifteen animals were treated with saline (1 ml x3) intraperitoneally at the time of RP, then at RP + 15 and RP + 30 min. Eleven rats received NBQX (30 mg/kg in 1 ml sterile water i.p.
x 3),9 rats received MK-801 (1 mg/kg in 1 ml saline i.p. x 3), and 11 rats received a combination of NBQX (30 mg/ kg i.p. X3) and MK-801 (1 mg/kg i.p. x3), all at the above times (RP, RP + 15, RP + 30 min). A final group (n = 10) received NBQX (90 mg/kg x 1) in 5% dextrose saline in travenously over a period of 4 h starting at RP. Experiment 2 (delayed NBQX). Seven animals received saline (1 ml i.p. X3) (RP, RP + 15, RP + 30 min), six animals received NBQX (30 mg/kg i.p. x3) immediately (RP, RP + 15, RP + 30 min), six animals received NBQX (30 mg/kg i.p. x3) following 6 h of RP [i.e., after a 6-h delay (6 h, 6 h + 15 min 6 h + 30 min)], six rats were treated following a 12-h delay (12 h, 12 h + 15 min, 12 h + 30 min), and five rats following a postischemic delay of 24 h (24 h, 24 h + 15 min, 24 h + 30 min).
Experiment 3 (GYKI 52466). Nine rats were given sa line (1 ml x5) at the time of RP and then at RP + 30, + 60, + 90, and + 120 min. GYKI 52466 (10 mg/kg x5) in 1-ml injections was given intraperitoneally to 11 animals at the above times.
Temperature was maintained until full recovery from both ischemia and drug administration (including delayed drug administration). The duration of coma was pro longed to 6-8 h in the rats treated with the combination of NBQX and MK-801; for rats treated with GYKI 52466, NBQX, or MK-80 1 alone, it was 3-4 h; while saline treated animals woke within 1-2 h.
Neuropathological analysis
Following ischemia, all animals were allowed to re cover and given free access to food and water for an RP period of 7 days. Animals were then reanesthetized and perfusion-fixed with a transcardiac infusion of 40% form aldehyde/glacial acetic acid/methanol (1: 1 :8). Brains were left in situ at 4°C overnight. Coronal sections of paraffin embedded brain 7 fl-m thick were cut, and the sections were stained with hematoxylin and eosin at several levels of the dorsal hippocampus (3.6 and 4.1 mm caudal to bregma) and for observation of striatal and cortical injury (0.2 and 1.6 mm rostral to bregma) (Paxinos and Watson, 1986) .
The identity of treatment groups was concealed during the histological examination. The CAl region of the hip pocampus was assessed by counting both the number of histologically normal-and abnormal-appearing CAl neu rons. The results are expressed as a percentage of dead neurons, defined as [(total CAl neurons -normal CAl neurons)/total CAl neurons] x 100 (Buchan et aI., 1991b) .
Statistical analysis
Differences in the percentage of dead CAl neurons and in grades of damage in the cortex and striatum were an alyzed by nonparametric statistics with the Kruskal Wallis test, and individual comparisons were then made with the Mann-Whitney U test using a Bonferroni cor rection. All group values are expressed as mean ± SD percentage CAl injury. An a priori sample size calcula tion was performed using control data from our labora tory. We calculated that to avoid missing a 30% reduction in hippocampal CAl injury, accepting an u of 0.05 and a 13 of 0. 2, six to nine animals per group would be needed.
These experiments were done with the approval of the Animal Care Committee of the Ottawa Civic Hospital, and the animals were cared for according to guidelines published by the National Institutes of Health and the Canadian Council on Animal Care.
RESULTS
One animal given NBQX delayed to 6 h died un expectedly. Treatment with the combination of the two drugs resulted in two deaths, so that only 9 of 11 animals were histologically analyzed. Six rats given intravenous NBQX were killed early because of a failure to thrive associated with renal damage with an NBQX-induced interstitial nephritis and plugging of the glomeruli (D. Xue et al., unpub lished data).
Experiment 1
The histopathological results are presented in Fig. 1 and show that the animals treated with saline (n = 15) sustained 81 ± 20% injured CAl neurons, but a significant reduction in damage was achieved in the group of animals treated with intraperitoneal NBQX (n = 11), resulting in 21 ± 27% (p < 0.01) injury. No protection was seen with MK-801 alone (n = 9), and the animals lost 83 ± 18% of the hip- pocampal CAl neurons. The protection was atten uated for animals treated with a combination of a cytoprotective dose of NBQX and MK-801 admin istration: Three of nine had some protection, but six did not, giving a mean of 54 ± 34% damaged cells, i.e. , not different from saline controls.
In Table 1 (Expt. 1), it can be seen that the 4 (of 10) survivors that received intravenous NBQX lost 94 ± 5% CAl neurons. It could be speculated that these animals had secondary damage to the CAl from NBQX-induced renal impairment.
Experiment 2
In Fig. 2 , it can be seen that the animals given delayed (6 and 12 h postischemia) intraperitoneal NBQX treatment were afforded similar CAl protec tion as those treated immediately. Saline-treated rats had 79 ± 16% CAl injury (n = 7), while NBQX (immediate RP) gave a value of 17 ± 17% (p < 0.01; n = 6) (Table 1, Expt. 2). Animals with treatment delayed by 6 h had 27 ± 32% injury (p < 0.01; n = 5), and, remarkably, those treated at 12 h had 25 ± 17% injury (p < 0.01; n = 6). A delay in the initi ation of treatment to 24 h resulted in partial protec tion to the lateral portion of CA I' but animals lost 50 ± 28% (n = 5), which did not significantly differ from the saline control values.
Experiment 3
No effect was discerned from immediate GYKI 52466 treatment. Saline-treated rats (n = 9) lost 81 ± 19% of CAl neurons, and those treated with GYKI 52466 (n = 11) lost 80 ± 14% (Table 1, Expt. 3). No toxicity was observed.
DISCUSSION
These data demonstrate the following points: (a) Immediate postischemic intraperitoneal administra tion of Na-NBQX (30 mg/kg x3) consistently pre vented selective ischemic death of the hippocampal CA I neurons following severe forebrain ischemia . (b) Delaying therapy with intraperitoneal NBQX for up to 12 h postischemia resulted in dramatic CAl cytoprotection. (c) Delaying treatment to 24 h postischemia resulted in the loss of the cytoprotec tive effect, which suggests that the critical interval for reversibility of threatened cell death is between 12 and 24 h. (d) We were unable to demonstrate any postischemic cytoprotective properties for MK-801 when used following RP. (e) A combination of the cytoprotective dose of intraperitoneal Na-NBQX plus intraperitoneal MK-801 attenuated the demon strated effects of NBQX. (0 GYKI 52466 (10 mg/kg x5) given intraperitoneally afforded no CAl protec tion. (g) NBQX given intravenously resulted in in- (11) Values are means ± SD of % hippocampal CAl injury (n). For abbreviations see the text. a p < 0.01, significantly reduced from saline controls. b NS; two animals died in this group, e Six animals died in this group. d One animal died in this group, travascular preclpltation and renal damage and failed to protect CAl pyramidal cells. These obser vations highlight the relative role of the AMP A re ceptor subtype vis-a-vis the NMDA glutamate re ceptor in postischemic CAl death. The exact mo lecular mechanism by which postischemic AMP A receptor agonism (and antagonism) leads to selec tive neuronal injury (and protection) remains uncer tain, but we demonstrate here that reversible mech anisms remain operant for at least 12, but not longer than 24 h.
Since glutamatergic lesions such as those to the Schaeffer collaterals protect CAl neurons from se- vere forebrain ischemia (Onodera et aI., 1986) , and NMDA receptor blockade is ineffective in the same models (Buchan et aI., 1991b; Nellgard et aI., 1991a) , glutamate receptors other than the NMDA receptor must be involved. NBQX, an analogue of the quinoxalinedione antagonists to the non-NMDA receptors (Honore et aI., 1988) , is a potent AMPA receptor antagonist that does not affect kainate re ceptors or the glycine or glutamate sites of the NMDA receptor and therefore allows the AMPA receptor ionophore to be selectively manipulated following ischemia (Sheardown et aI., 1990) . Fur thermore, NBQX does not antagonize the quis qualate metabotropic receptor (Suzdak et aI., 1990) , which, when blocked in vitro, may prevent hypox ia-induced CAl pyramidal cell death (Opitz and Reymann, 1991) , although there is as yet no com parable in vivo data with metabotropic glutamate receptor blockade. In this study (using 10 mg/kg x5), GYKI 52466 was not successful in preventing CAl injury, nor was it able to prevent the death of CAl neurons in another study in which protection was demon strated for the striatum and cortex (LePeillet et aI., 1992) . Favorable results might have been achieved with higher doses of GYKI 52466 since it can block the CAl field potentials evoked in an in vitro slice preparation in a dose-dependent fashion, with �100% inhibition at 80 f.lM (Tarnawa et aI., 1992) . Our dose of 10 mg/kg would have completely blocked the evoked reflex potentials in the spinal cord, but only weak inhibition might have been achieved for CAl (Tarnawa et aI., 1990) . In a study now underway, we are testing higher doses of GYKI 52466 (30 mg/kg x 5) to see if this will protect CAl neurons (A. M. Buchan et aI., unpublished data).
To explain why MK-801 attenuated the cytopro tective effects of NBQX, a number of hypotheses can be offered. The use of the channel blocker MK-801 might prevent or interfere with the optimal binding of NBQX to the AMPA receptor. NBQX, given intraperitoneally, readily precipitates in the peritoneal space, and the combination of MK-801 and NBQX could affect not only this precipitation but the subsequent absorption of NBQX with a re duction in extracellular levels of NBQX below a critical value. Postischemic NBQX given alone in this dose (30 mg/kg i.p. x3) reaches 1 f.LM concen trations (M. J. Sheardown et aI., personal commu nication, 1993) , but extracellular concentrations of NBQX when coadministered with MK-801 have not been reported. A third possibility is that cells resus citated with NBQX remain precarious and vulner able to secondary insults. MK-801 treatment is po tentially toxic to neurons. In our normothermic 4VO animals, to which we gave comparable doses of MK-801 prior to ischemia, we actually induced significantly more CAl injury in MK-801-treated animals as compared with saline controls following 15-min forebrain ischemia (Buchan et aI., 1991b) . MK-801 administration alone can produce patho logical changes in cingulate neurons, i. e., in the ab sence of ischemia (Olney et aI., 1989) , via a mech anism coupled to the NMDA receptor (Olney et aI., 1991) . Although it is claimed that MK-801 does not induce permanent damage (Allan and Iversen, 1990) , NBQX-resuscitated CAl neurons may have enhanced sensitivity to the "toxic" effects of MK-801. We are currently exploring this interaction by delaying our MK-801 cotreatment and have prelim inary data to suggest that if MK-801 is given 24 h following NBQX (given at the time of RP), we can still attenuate the cytoprotective response of NBQX (A. M. Buchan et aI., unpublished data) .
The postischemic normalization of ATP levels and extracellular pH following transient cerebral ischemia occurs over the same period of time as does normalization of extracellular concentrations of glutamate, aspartate, and glycine (i.e., within minutes of recirculation in the CAl hippocampus of rats SUbjected to 4VO ischemia). Following this, there is no overt or secondary excessive rise for up to 24 h after cerebral reperfusion (Cho and Pulsinelli, 1991) , i.e., during the interval in which delayed administration of NBQX is still actively able to afford cytoprotection . These observations, combined with our find ing that AMPA antagonists markedly attenuate CAl damage when administered up to 12 h after cerebral recirculation, suggest that glutamate release and "excitotoxic" stimulation of AMPA receptors dur-ing ischemia are not the unifying explanation for ischemic injury to these neurons. The dramatic ef fectiveness of delayed NBQX treatment suggests that acquired disturbances in postsynaptic AMP A receptor channel sensitivity or channel "up regulation" may explain the selective sensitivity. Andine et al. (1988) have measured the drop in ex tracellular calcium following stimulation of the en torhinal cortex and shown that following forebrain ischemia, the stimulation-induced decrease is larger, implying up-regulation of calcium-permeable ion channels. These extracellular Ca 2+ declines were partially depressed by MK-801, but com pletely prevented by NBQX (Andine et aI., 1992) .
It has recently become clear that specific hetero meric combinations of the AMP A receptor subunits (GluRl, GluR 2 , GluR3, and GluR4), expressed in oocytes, are also permeable to calcium ions (Holl mann et aI., 1991) and that Ca 2+ conduction com binations of AMP A receptor subunits exist in reti nal bipolar cells (Gilbertson et aI., 1991) , glial cells (Muller et aI., 1992) , and some hippocampal neu rons (Iino et aI., 1990) . A plausible hypothesis is that Ca 2 + influx through selective AMP A-regulated ionophores during cerebral recirculation is the mechanism of CAl cell death (and hence the pro tection afforded by NBQX). The four polypeptides, GluRl to GluR4, constitute the family of subunits for receptors with a high affinity for AMP A and a low affinity for kainate (Hollmann et aI., 1991; Monyer et aI., 1992) . In heteromeric assemblies, GluR 2 dictates the conductance and permeability properties of the channel (Hume et aI., 1991; Ver doom et aI., 1991) . When expressed in Xenopus oocytes alone or in combination, GluRl and GluR3 form receptors that have a substantial Ca + + per meability, but when GluR 2 is coexpressed, the re ceptor channels have little or no Ca 2 + permeability (Hollmann et aI., 1991; Meguro et aI., 1992) . The elegant observation in postischemic CAl that mRNA ratios indicate a relative loss of mRNA for GluR 2 in the CAl zone (Pellegrini-Giampietro et aI., 1992) suggests a switch in glutamate receptor sub unit expression and a potential mechanism for a postischemic increase in Ca 2+ permeability through channels linked to AMPA receptors. This change in the ratio occurs in CAl but does not occur in the relatively resistant CA3 pyramidal cells (Pellegrini Giampietro et aI., 1992) . An increased expression of Ca 2 + -porous AMP A-linked channels might then ac count for the susceptibility of CAl in the postisch emic period and the ability of delayed NBQX treat ment to prevent intracellular Ca 2 + currents (Andine et aI., 1992) and subsequent CAl necrosis even when given 12 h later.
Another potential mechanism can be conjectured by the observations that AMP A receptors metamor phose; i.e., a modified heteromeric receptor/ channel may be configured to increase its sensitiv ity to glutamate or to accentuate its Ca 2 + ion con ductivity (Nellgard et al., 1991b) . Mutational analysis of the GluRI-GluR4 receptor subunits has revealed that the identity of a single amino acid res idue (arginine or glutamine) located at a specific transmembrane site in the putative channel-forming regions determines channel permeability to Ca 2 + (Rume et al., 1991) . The presence of arginine pre vents Ca 2 + permeability in GluR 2 -expressed chan nels. This specific determinant is not encoded by the genomic DNA for Glu receptor subunits, but appears to be introduced by posttranslational RNA editing (Sommer et al., 1990 (Sommer et al., , 1991 , with the CAG codon for glutamine converted to an edited CIG codon for arginine, i.e., adenosine switched for ino sine in the edited mRNA (Sommer et al., 1990; Bur nashev et al., 1992) . One speculative hypothesis would be that there is a malfunction in the acquired RNA editing that could be caused by excessive glu tamate-activated (? ischemic) Ca 2 + influx.
CONCLUSION
Most encouraging clinically, and revealing mech anistically, is our ability to profoundly delay treat ment with NBQX and still interrupt the cascades that eventuate in cell death. This may give us ther apeutic windows of up to 12, but not 24, h to protect the hippocampi of patients surviving cardiac arrest. Assuming NBQX has a specific action, since we are able to confirm a dramatic reduction of CAl injury with delayed AMPA but not NMDA blockade, then the inference is that AMP A receptors are critically linked to the delayed pathogenesis of CAl injury. Data are also now emerging that indicate that both NBQX and GYKI 52466 can also protect the cortex in the wake of focal ischemia (Buchan et al., 1991c; Gill et al., 1992; Smith and Meldrum, 1992; D. Xue et al., unpublished data) .
If these drugs can be established to be safe from a toxicological standpoint, then clinical stroke trials should be pursued with enthusiasm.
